UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

CA: a cancer journal for clinicians, 2013-07, Vol.63 (4), p.249-279

2013

Volltextzugriff (PDF)

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies

British journal of cancer, 2017-06, Vol.116 (12), p.1505-1512

2017

Volltextzugriff (PDF)

A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors

Investigational new drugs, 2020-12, Vol.38 (6), p.1755-1762

2020

Volltextzugriff (PDF)

A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients

American journal of clinical oncology, 2019-02, Vol.42 (2), p.184-189

2019

Volltextzugriff (PDF)

A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors

Investigational new drugs, 2015-02, Vol.33 (1), p.225-232

2015

Volltextzugriff (PDF)

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

Investigational new drugs, 2015-02, Vol.33 (1), p.159-168

2015

Volltextzugriff (PDF)

A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer

Clinical cancer research, 2005-05, Vol.11 (9), p.3410-3416

2005

Volltextzugriff (PDF)

KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

The New England journal of medicine, 2020-09, Vol.383 (13), p.1207-1217

2020

Volltextzugriff (PDF)

A Phase I Trial of the Novel Farnesyl Protein Transferase Inhibitor, BMS-214662, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Cancer

Clinical cancer research, 2005-03, Vol.11 (5), p.1877-1883

2005

Volltextzugriff (PDF)

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies

Investigational new drugs, 2013-08, Vol.31 (4), p.967-973

2013

Volltextzugriff (PDF)

Phase 1b study of the oral gemcitabine ‘Pro-drug’ LY2334737 in combination with capecitabine in patients with advanced solid tumors

Investigational new drugs, 2015-04, Vol.33 (2), p.432-439

2015

Volltextzugriff (PDF)

Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing

BMC medical informatics and decision making, 2019-01, Vol.19 (1), p.14-14, Article 14

2019

Volltextzugriff (PDF)

Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Clinical cancer research, 2013-03, Vol.19 (5), p.1232-1243

2013

Volltextzugriff (PDF)

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors

Investigational new drugs, 2013-08, Vol.31 (4), p.927-936

2013

Volltextzugriff (PDF)

A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies

Cancer chemotherapy and pharmacology, 2013-05, Vol.71 (5), p.1273-1285

2013

Volltextzugriff (PDF)

Obstacles and opportunities in the clinical development of targeted therapeutics

Progress in drug research, 2005, Vol.63, p.19

2005

Volltextzugriff (PDF)

A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer

Cancer chemotherapy and pharmacology, 2005-12, Vol.56 (6), p.623-628

2005

Volltextzugriff (PDF)

A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2005-06, Vol.55 (6), p.522-530

2005

Volltextzugriff (PDF)

Novel pharmacological agents in clinical development for solid tumours

Expert opinion on investigational drugs, 2001-12, Vol.10 (12), p.2059-2088

2001

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Aktive Filter

ThemaNeoplasms - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(21)
Life Sciences & Biomedicine
(18)
Science & Technology
(18)
Oncology
(16)
Female
(15)
Male
(15)
Middle Aged
(15)
Aged
(13)
Adult
(11)
Pharmacology & Pharmacy
(10)
Tumors
(10)
Aged, 80 And Over
(9)
Maximum Tolerated Dose
(9)
Medicine
(9)
Antineoplastic Agents
(8)
Antineoplastic Agents - Adverse Effects
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(8)
Biological And Medical Sciences
(8)
Medical Sciences
(8)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Understanding, recognizing, and managing toxicities of targeted anticancer therapies

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies

A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors

A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients

A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer

KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

A Phase I Trial of the Novel Farnesyl Protein Transferase Inhibitor, BMS-214662, in Combination with Paclitaxel and Carboplatin in Patients with Advanced Cancer

A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies

Phase 1b study of the oral gemcitabine ‘Pro-drug’ LY2334737 in combination with capecitabine in patients with advanced solid tumors

Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing

Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors

A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Obstacles and opportunities in the clinical development of targeted therapeutics

A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer

A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors

Novel pharmacological agents in clinical development for solid tumours

Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis

Aktive Filter

Suchergebnisse filtern